<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene A67V;H69del;V70del;T95I;G142D;G142D;V143del;Y144del;Y145del;G339D;S375F;K417N;N440K;S477N;T478K;E484A;Q493R;N501Y;Y505H;T547K;D614G;H655Y;N679K;P681H;N764K;D796Y;N856K;Q954H;N969K;L981F literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.A67V;H69_V70del;T95I;G142D;G142D;V143_Y144_Y145del;G339D;S375F;K417N;N440K;S477N;T478K;E484A;Q493R;N501Y;Y505H;T547K;D614G;H655Y;N679K;P681H;N764K;D796Y;N856K;Q954H;N969K;L981F</span> literature reference collection</h1>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Omicron (a.k.a. B.1.1.529) Spike pseudotyped VSV and Vero E6 cells has somewhat  reduced neutralization (2.7x) vs wild type with monoclonal antibody Sotrovimab (a.k.a. VIR-7831). <br/> [delins at 214 omitted for syntax compatibility] (<a href="https://doi.org/10.1101/2021.03.09.434607v9" class="lit_link">Cathcart et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Omicron breakthrough infection after 3-dose vaccination resulted in a further 3.5-fold and 2.9-fold increase of Omicron BA.1 and BA.2 neutralizing titers. Omicron  BA.4/5 showed the highest neutralization resistance of all variants tested, resulting in low geometric mean neutralizing titers in plasma samples  obtained after  the second vaccine dose (NT50=72).<br/> (<a href="https://doi.org/10.1101/2022.08.11.503601" class="lit_link">Wang et al. (2022)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
